Table of Contents
<< Previous Issue | Jun 2016 (Vol: 2016, Issue: 6) | Next Issue >> |
- Section: Licensing
-
Janssen Biotech Secures Another DART Molecule in US$740 M Deal with MacroGenics
-
Biogen Revamps its Outlook by Licensing Next Generation Gene Therapies
- Section: Mergers & Acquisitions
-
Pfizer Returns to Deal Making with Anacor Acquisition
-
Merck & Co’s Neurology Boost with Afferent Acquisition
-
Promising AML Therapy Draws Jazz to US$1.5 B Acquisition of Celator
- Section: Research & Development
-
Celgene Spreads its Bets in Immuno-Oncology via New Deal with Agios